Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

Active Filters

    Open
    Phase
    Accrual
    24%
    SWOG Clinical Trial Number
    S2104
    Closed
    Phase
    Accrual
    3%
    SWOG Clinical Trial Number
    S2011

    Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL

    Status Notes
    The study referenced above is closed to participant accrual effective November 15th, 2023, at 3:00 p.m. Eastern Time.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    10-06-2021
    Closed
    11-15-2023
    ClinicalTrials.gov Registry Number
    04871529
    Closed
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S1934

    NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer

    Status Notes
    S1934 is permanently closed effective 3/1/2023.
    Research Committee(s)
    Lung Cancer
    Activated
    09-09-2021
    Closed
    03-01-2023
    ClinicalTrials.gov Registry Number
    04989283
    Open
    Phase
    Accrual
    94%
    SWOG Clinical Trial Number
    S2013

    Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

    Status Notes
    S2013 will open to accrual on August 16, 2021, effective 12:00 pm PST.
    Research Committee(s)
    Symptom Control and Quality of Life
    Activated
    08-16-2021
    Open
    Phase
    Accrual
    66%
    SWOG Clinical Trial Number
    S1912CD

    A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

    Status Notes
    All protocol documents will be accessible from the S1912CD protocol abstract page on www.ctsu.org (login required).
    Research Committee(s)
    Cancer Care Delivery
    Activated
    07-26-2021
    ClinicalTrials.gov Registry Number
    NCT 04960787
    Open
    Phase
    Accrual
    2%
    SWOG Clinical Trial Number
    S2005

    A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)

    Status Notes
    Re-Activation – Effective (9/20/2021)
    Research Committee(s)
    Myeloma
    Activated
    06-24-2021
    ClinicalTrials.gov Registry Number
    04840602
    Open
    Phase
    Accrual
    96%
    SWOG Clinical Trial Number
    S1900E

    A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)

    Status Notes
    S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    04-02-2021
    Open
    Phase
    Accrual
    22%
    SWOG Clinical Trial Number
    S1918

    A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

    Status Notes
    Activation - Effective 3/19/21, 12:00 pm Pacific Time

    Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.

    Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.

    Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
    Research Committee(s)
    Lymphoma
    Activated
    03-19-2021
    ClinicalTrials.gov Registry Number
    04799275
    Open
    Phase
    Accrual
    14%
    SWOG Clinical Trial Number
    S1937

    A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.

    Status Notes
    Arm 2 will be Permanently Closed to Accrual and Arms 1 & 3 will be Reopened to Accrual as of 02/15/2024, 12 PM PST.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    02-16-2021
    ClinicalTrials.gov Registry Number
    NCT04579224
    Open
    Phase
    Accrual
    55%
    SWOG Clinical Trial Number
    S2007

    A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

    Status Notes
    Activation - Effective 12/15/20, 12:00 PM Pacific Time

    All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
    Research Committee(s)
    Breast Cancer
    Activated
    12-15-2020
    ClinicalTrials.gov Registry Number
    04647916
    Open
    Phase
    Accrual
    38%
    SWOG Clinical Trial Number
    S1925

    A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

    Status Notes
    Active effective 12/14/20
    Research Committee(s)
    Leukemia
    Lymphoma
    Symptom Control and Quality of Life
    Activated
    12-14-2020
    ClinicalTrials.gov Registry Number
    04269902
    Open
    Phase
    Accrual
    53%
    SWOG Clinical Trial Number
    S2001

    Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects

    Status Notes
    Activation, Effective 12/04/2020, 3:00 pm eastern
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    12-04-2020
    ClinicalTrials.gov Registry Number
    NCT04548752
    Open
    Phase
    Accrual
    27%
    SWOG Clinical Trial Number
    S1931

    Phase III trial of Nivolumab and Ipilimumab with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

    Status Notes
    Active effective 11/16/2020
    Research Committee(s)
    Genitourinary Cancer
    Activated
    11-16-2020
    Open
    Phase
    Accrual
    91%
    SWOG Clinical Trial Number
    S2000

    A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

    Status Notes
    Activation, Effective 9/23/2020, 2:00 pm eastern
    Research Committee(s)
    Melanoma
    Activated
    09-23-2020
    ClinicalTrials.gov Registry Number
    NCT04511013
    Open
    Phase
    Accrual
    93%
    Open
    Phase
    Accrual
    22%
    SWOG Clinical Trial Number
    S1905

    A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

    Status Notes
    Re-opened to accrual effective: 10/02/2023.
    Research Committee(s)
    Leukemia
    Activated
    08-17-2020
    ClinicalTrials.gov Registry Number
    NCT#04315324
    Open
    Phase
    Accrual
    74%
    SWOG Clinical Trial Number
    S1933

    A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status

    Status Notes
    This study is open to accrual effective June 15, 2020 at 12:00 p.m. Pacific.
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2020
    ClinicalTrials.gov Registry Number
    NCT04310020
    Closed
    Phase
    Accrual
    100%
    SWOG Clinical Trial Number
    S1929

    Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC)

    Status Notes
    S1929 will open to accrual June 15, 2020, effective 12:00 pm PST.

    Effective August 15, 2022, at 3:45 a.m. Pacific Time, S1929 Step 1 Screening Registration will be permanently closed to accrual, as it has met the protocol specified accrual goal.
    Research Committee(s)
    Lung Cancer
    Activated
    06-15-2020
    Closed
    12-15-2022
    ClinicalTrials.gov Registry Number
    04334941
    Open
    Phase
    Accrual
    96%
    SWOG Clinical Trial Number
    S1823

    A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors

    Status Notes
    Effective April 15, 2022, the study will be partial permanently closed to the high risk of relapse group (except for testicular nonseminoma Stage IS).
    Research Committee(s)
    Prevention & Epidemiology
    Genitourinary Cancer
    Activated
    06-01-2020
    Open
    Phase
    Accrual
    71%
    SWOG Clinical Trial Number
    S1914

    A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

    Status Notes
    This study is open to accrual effective March 25, 2020.
    Research Committee(s)
    Lung Cancer
    Activated
    03-25-2020
    ClinicalTrials.gov Registry Number
    04214262